These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17827006)

  • 1. N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.
    Huang W; Zheng W; Urban DJ; Inglese J; Sidransky E; Austin CP; Thomas CJ
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5783-9. PubMed ID: 17827006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A; Llebaria A
    Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?
    Trapero A; Llebaria A
    Future Med Chem; 2014 Jun; 6(9):975-8. PubMed ID: 25068980
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.
    Cheng WC; Weng CY; Yun WY; Chang SY; Lin YC; Tsai FJ; Huang FY; Chen YR
    Bioorg Med Chem; 2013 Sep; 21(17):5021-8. PubMed ID: 23880081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.
    Zheng W; Padia J; Urban DJ; Jadhav A; Goker-Alpan O; Simeonov A; Goldin E; Auld D; LaMarca ME; Inglese J; Austin CP; Sidransky E
    Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13192-7. PubMed ID: 17670938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease.
    Parmeggiani C; Catarzi S; Matassini C; D'Adamio G; Morrone A; Goti A; Paoli P; Cardona F
    Chembiochem; 2015 Sep; 16(14):2054-64. PubMed ID: 26376302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
    Trapero A; Alfonso I; Butters TD; Llebaria A
    J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase.
    Adams BT; Niccoli S; Chowdhury MA; Esarik AN; Lees SJ; Rempel BP; Phenix CP
    Chem Commun (Camb); 2015 Jul; 51(57):11390-3. PubMed ID: 26085065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.
    Schönemann W; Gallienne E; Ikeda-Obatake K; Asano N; Nakagawa S; Kato A; Adachi I; Górecki M; Frelek J; Martin OR
    ChemMedChem; 2013 Nov; 8(11):1805-17. PubMed ID: 24115322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
    Marugan JJ; Zheng W; Motabar O; Southall N; Goldin E; Westbroek W; Stubblefield BK; Sidransky E; Aungst RA; Lea WA; Simeonov A; Leister W; Austin CP
    J Med Chem; 2011 Feb; 54(4):1033-58. PubMed ID: 21250698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
    Trapero A; González-Bulnes P; Butters TD; Llebaria A
    J Med Chem; 2012 May; 55(9):4479-88. PubMed ID: 22512696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity.
    Stauffert F; Serra-Vinardell J; Gómez-Grau M; Michelakakis H; Mavridou I; Grinberg D; Vilageliu L; Casas J; Bodlenner A; Delgado A; Compain P
    Org Biomol Chem; 2017 May; 15(17):3681-3705. PubMed ID: 28401966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailoring the specificity and reactivity of a mechanism-based inactivator of glucocerebrosidase for potential therapeutic applications.
    Rempel BP; Tropak MB; Mahuran DJ; Withers SG
    Angew Chem Int Ed Engl; 2011 Oct; 50(44):10381-3. PubMed ID: 21915968
    [No Abstract]   [Full Text] [Related]  

  • 15. Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease.
    Rudensky B; Paz E; Altarescu G; Raveh D; Elstein D; Zimran A
    Blood Cells Mol Dis; 2003; 30(1):97-9. PubMed ID: 12667991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
    Tropak MB; Kornhaber GJ; Rigat BA; Maegawa GH; Buttner JD; Blanchard JE; Murphy C; Tuske SJ; Coales SJ; Hamuro Y; Brown ED; Mahuran DJ
    Chembiochem; 2008 Nov; 9(16):2650-62. PubMed ID: 18972510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocerebrosidase enhancers for selected Gaucher disease genotypes by modification of α-1-C-substituted imino-D-xylitols (DIXs) by click chemistry.
    Serra-Vinardell J; Díaz L; Casas J; Grinberg D; Vilageliu L; Michelakakis H; Mavridou I; Aerts JM; Decroocq C; Compain P; Delgado A
    ChemMedChem; 2014 Aug; 9(8):1744-54. PubMed ID: 24976039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Guanidino Derivatives of 1,5-Dideoxy-1,5-imino-d-xylitol are Potent, Selective, and Stable Inhibitors of β-Glucocerebrosidase.
    Sevšek A; Šrot L; Rihter J; Čelan M; van Ufford LQ; Moret EE; Martin NI; Pieters RJ
    ChemMedChem; 2017 Apr; 12(7):483-486. PubMed ID: 28328014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring substituent diversity on pyrrolidine-aryltriazole iminosugars: Structural basis of β-glucocerebrosidase inhibition.
    Martínez-Bailén M; Carmona AT; Patterson-Orazem AC; Lieberman RL; Ide D; Kubo M; Kato A; Robina I; Moreno-Vargas AJ
    Bioorg Chem; 2019 May; 86():652-664. PubMed ID: 30825709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.